

Supplementary Table 1. GSEA Enrichment Scores

| NAME | ES ¹ | NES ² | NOM p-val | FDR q-val |
|--|-----------------|------------------|-------------|------------|
| HALLMARK_MITOTIC_SPINDLE | -0.96953654 | -2.738665 | 0.036809817 | 0.24540035 |
| HALLMARK_TNFA_SIGNALING_VIA_NFKB | -0.78459835 | -2.131841 | 0.061099797 | 1 |
| HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | -0.7627758 | -2.1261334 | 0.064718165 | 0.6822187 |
| HALLMARK_INTERFERON_GAMMA_RESPONSE | -0.75405574 | -2.0704424 | 0.06290673 | 0.5373365 |
| HALLMARK_XENOBIOTIC_METABOLISM | 0.7114698 | 1.7093651 | 0.14814815 | 0.8671167 |
| HALLMARK_ANGIOGENESIS | -0.7054058 | -1.7550359 | 0.047528517 | 0.33538553 |
| HALLMARK_ESTROGEN_RESPONSE_EARLY | 0.70333433 | 1.7096115 | 0.14570858 | 1 |
| HALLMARK_COMPLEMENT | -0.6963707 | -1.8607478 | 0.08898305 | 0.5260123 |
| HALLMARK_ESTROGEN_RESPONSE_LATE | 0.69636387 | 1.6763769 | 0.13644859 | 0.6136178 |
| HALLMARK_OXIDATIVE_PHOSPHORYLATION | 0.68012977 | 1.6174641 | 0.17375231 | 0.51181173 |
| HALLMARK_KRAS_SIGNALING_UP | -0.6740996 | -1.8120219 | 0.09544469 | 0.46603143 |
| HALLMARK_INFLAMMATORY_RESPONSE | -0.66156536 | -1.8029977 | 0.10107527 | 0.4036422 |
| HALLMARK_HYPOXIA | -0.6506489 | -1.7506601 | 0.11594203 | 0.3033227 |
| HALLMARK_INTERFERON_ALPHA_RESPONSE | -0.6433157 | -1.8028818 | 0.057539683 | 0.35318694 |
| HALLMARK_MYC_TARGETS_V1 | -0.63430864 | -1.6890604 | 0.12035011 | 0.30162588 |
| HALLMARK_IL6_JAK_STAT3_SIGNALING | -0.6031751 | -1.66111 | 0.06584362 | 0.28307122 |
| HALLMARK_SPERMATOGENESIS | -0.5676277 | -1.557379 | 0.061099797 | 0.28568843 |
| HALLMARK_HEDGEHOG_SIGNALING | -0.5453301 | -1.3602403 | 0.13793103 | 0.29140854 |
| HALLMARK_APOPTOSIS | -0.5123841 | -1.419991 | 0.111561865 | 0.30515093 |
| HALLMARK_PANCREAS_BETA_CELLS | 0.50091386 | 1.2124683 | 0.23517382 | 0.6139624 |
| HALLMARK_GLYCOLYSIS | 0.5003059 | 1.1435319 | 0.256654 | 0.48104674 |
| HALLMARK_MYOGENESIS | -0.4992916 | -1.3265461 | 0.14197531 | 0.27315947 |
| HALLMARK_ALLOGRAFT_REJECTION | -0.49219608 | -1.3456522 | 0.12778905 | 0.28104284 |
| HALLMARK_UV_RESPONSE_DN | -0.4788568 | -1.3921219 | 0.09381663 | 0.29563344 |
| HALLMARK_IL2_STAT5_SIGNALING | -0.4648526 | -1.2194562 | 0.1826087 | 0.32190385 |
| HALLMARK_PEROXISOME | 0.45880708 | 1.1639911 | 0.21142857 | 0.5433961 |
| HALLMARKADIPOGENESIS | 0.42392758 | 1.0107353 | 0.29338843 | 0.5345546 |
| HALLMARK_G2M_CHECKPOINT | -0.42264763 | -1.1181176 | 0.18828452 | 0.39563367 |
| HALLMARK_NOTCH_SIGNALING | -0.41112712 | -1.0035685 | 0.41614908 | 0.5054806 |
| HALLMARK_TGF_BETA_SIGNALING | -0.38988957 | -1.0531788 | 0.34435797 | 0.45401844 |
| HALLMARK_BILE_ACID_METABOLISM | 0.37280008 | 0.92135537 | 0.38345864 | 0.5846342 |
| HALLMARK_COAGULATION | -0.35666084 | -0.96529174 | 0.36305732 | 0.55080724 |
| HALLMARK_P53_PATHWAY | -0.35356408 | -0.9617617 | 0.28817204 | 0.5333001 |
| HALLMARK_E2F_TARGETS | -0.3495585 | -0.89524615 | 0.31905782 | 0.5649946 |
| HALLMARK_FATTY_ACID_METABOLISM | 0.3491053 | 0.86028254 | 0.4208494 | 0.6140024 |
| HALLMARK_PI3K_AKT_MTOR_SIGNALING | -0.34672815 | -0.9346718 | 0.4032258 | 0.5377159 |
| HALLMARK_APICAL_SURFACE | -0.34615594 | -0.9051891 | 0.53373015 | 0.5665438 |
| HALLMARK_CHOLESTEROL_HOMEOSTASIS | -0.34555647 | -0.9500684 | 0.43452382 | 0.5313629 |
| HALLMARK_ANDROGEN_RESPONSE | 0.31548336 | 0.7782141 | 0.5708333 | 0.7003621 |
| HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY | -0.3002477 | -0.81362534 | 0.6687631 | 0.70644766 |
| HALLMARK_WNT_BETA_CATENIN_SIGNALING | -0.29808396 | -0.766772 | 0.7231076 | 0.73594713 |

| | | | | |
|------------------------------------|-------------|-------------|------------|------------|
| HALLMARK_PROTEIN_SECRETION | 0.29019544 | 0.6923406 | 0.65957445 | 0.80639565 |
| HALLMARK_MYC_TARGETS_V2 | -0.28258362 | -0.77286494 | 0.69753087 | 0.74765736 |
| HALLMARK_DNA_REPAIR | -0.27484703 | -0.77776295 | 0.6492693 | 0.7620492 |
| HALLMARK_UV_RESPONSE_UP | -0.26478726 | -0.7135497 | 0.73100615 | 0.8207212 |
| HALLMARK_MTORC1_SIGNALING | -0.25699028 | -0.6710301 | 0.7731481 | 0.87532324 |
| HALLMARK_KRAS_SIGNALING_DN | 0.25573143 | 0.64437884 | 0.83943087 | 0.83299124 |
| HALLMARK_APICAL_JUNCTION | -0.23773567 | -0.65685195 | 0.8586724 | 0.87192327 |
| HALLMARK_UNFOLDED_PROTEIN_RESPONSE | 0.22921126 | 0.56387246 | 0.8996139 | 0.90224123 |
| HALLMARK_HEME_METABOLISM | -0.22914925 | -0.6322403 | 0.8836689 | 0.88378996 |

¹Enrichment Score: Degree to which gene set is overrepresented at the top or bottom of the ranked list of genes.

²Normalized Enrichment Score: Enrichment score divided by the mean of enrichment scores against all permutations of the ranked list.


Supplemental Table 2. Ancestry Proportion Permutation Test Summary Statistics

| Statistic | Value |
|--|-------------|
| Minimum | -0.619 |
| 1st Quartile | -0.227 |
| Median | 0.013 |
| Mean | -0.005 |
| 3rd Quartile | 0.210 |
| Maximum | 0.567 |
| P Value of True Correlation¹ | 0.05 |

¹Based on the ranking of true correlation ($c = 0.43$) out of 1000 permutation tests.

Supplemental Figure 1. Case-Control, Disease Subtype, and Medication

Associations with DEGs



(a) First principal component (PC1) of genes differentially expressed between IBD cases and controls. $P = 1.42 \times 10^{-6}$ **(b)** PC1 of case-control DEGs in AA and European individuals. $P = 0.15$ **(c)** PC1 of genes differentially expressed between AA and European IBD patients in IBD cases and controls. $P = 0.27$ **(d)** First principal component of genes differentially expressed between AA and European IBD patients. $P = 1.38 \times 10^{-6}$ **(e)** PC1 of ancestry-related DEGs in controls and subtypes of IBD. $P = 0.54$ **(f)** PC1 of ancestry-related DEGs in patients known to be treated with steroids. $P = 9.22 \times 10^{-6}$; note that only AA patients received steroids **(g)** PC1 of ancestry-related DEGs in patients known to be treated with anti-TNF. $P = 0.44$ **(h)** PC1 of ancestry-related DEGs in patients known to be treated with immunomodulators. $P = 0.94$